Performance in Q4 was characterized as a period of 'control' rather than acceleration, focusing on establishing a predictable and repeatable operating model. The company successfully resolved significant reimbursement uncertainty, with six of seven Medicare Administrative Contractors (MACs) now publishing payment rates for ReCell. Commercial strategy has been refined to prioritize utilization and repeat use within approximately 200 core burn and trauma centers rather than aggressive new account acquis ...

Core Insights - The company is experiencing a normalization in the utilization of its products, particularly ReCell, as reimbursement clarity improves, which is crucial for driving growth [1][2][3] - The fourth quarter of 2025 showed revenue of $17.6 million, with a full-year revenue of approximately $71.6 million, reflecting an 11% growth over 2024 [3][11] - The company expects full-year revenue for 2026 to be between $80 million and $85 million, indicating a growth of approximately 12% to 19% over 2025 [10][11] Revenue and Financial Performance - The fourth quarter revenue of $17.6 million was consistent with revised expectations, while the full-year revenue of $71.6 million marked a consecutive year of growth despite reimbursement challenges [11][12] - Gross margin for the full year was 82.1%, down from 85.8% in 2024, attributed to product mix and inventory reserves [11][12] - Operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to reduced sales and marketing expenses [13][14] Product Utilization and Strategy - The company is focusing on increasing adoption and repeated use of its products—ReCell, CoHiliX, and PermeDerm—within core burn and trauma centers, which account for roughly 90% of revenue [1][5] - ReCell remains the foundation of the business, supported by clinical evidence demonstrating faster healing and improved outcomes [6][7] - The company is transitioning from a ReCell-only strategy to a multiproduct acute wound care platform, which is expected to enhance revenue per patient opportunities [7] Reimbursement and Market Dynamics - Six of the seven Medicare Administrative Contractors (MACs) have published payment rates for ReCell procedures, alleviating previous reimbursement uncertainties [2][25] - The company is actively engaging with the remaining MAC to ensure reimbursement clarity and is optimistic about future developments [25][26] - The focus on establishing a disciplined operating model and improved visibility into cash use is expected to support execution and growth [4][14] Future Outlook - The company aims to maintain disciplined control of operating costs while supporting revenue growth with a stable cost structure [16][17] - The refinancing of debt through a new credit facility is designed to reduce operational friction and support execution [9][15] - The strategy for 2026 includes a commitment to clear reporting and execution, with a focus on delivering on established milestones [18]